Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Spotlight: Bio2 Technologies Inc., Space-Tech Biomaterial For Extremities Surgery

Executive Summary

Originating from aerospace technology, Bio2 Technologies’ Vitrium biomaterial platform is designed for multiple applications across musculoskeletal surgery. The firm has already begun commercialization in the US and expects to get a CE mark later this year.

You may also be interested in...



Perrigo Reaches Year Anniversary For First OTC Brand Switch With Sixth Packaging Approval

Latest FDA approval for mometasone furoate, 50-mcg metered spray, is for three 144-spray containers. Nasonex 24HR Allergy is Perrigo’s first OTC switch of national brand and first mometasone furoate offered nonprescription in US.

Perrigo Plays Customary Card For Approval Of First OTC Ibuprofen-Acetaminophen Generic In US

First generic of Haleon Advil Dual Action approved as brand lost three-year market exclusivity and day after Perrigo announced end of phase 1 of turnaround strategy and start of starting phase 2.

Health Care Professionals Settle With FTC Over COVID-19 Claims For Direct Seller’s Supplements

Three distributors made claims doTerra's essential oils and supplements could treat or prevent COVID-19 in early 2022webinars. They also underscored medical expertise in recommending products.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel